key: cord-0740574-c7erjd0c
authors: van der Heide, Verena; Jangra, Sonia; Cohen, Phillip; Rathnasinghe, Raveen; Aslam, Sadaf; Aydillo, Teresa; Geanon, Daniel; Handler, Diana; Kelley, Geoffrey; Lee, Brian; Rahman, Adeeb; Dawson, Travis; Qi, Jingjing; D’Souza, Darwin; Kim-Schulze, Seunghee; Panzer, Julia K.; Caicedo, Alejandro; Kusmartseva, Irina; Posgai, Amanda L.; Atkinson, Mark A.; Albrecht, Randy A.; García-Sastre, Adolfo; Rosenberg, Brad R.; Schotsaert, Michael; Homann, Dirk
title: Limited Extent and Consequences of Pancreatic SARS-CoV-2 Infection
date: 2022-02-21
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110508
sha: 1e2790c8b0e3529cf633828fb0e68908649750c0
doc_id: 740574
cord_uid: c7erjd0c

Concerns that infection with SARS-CoV-2, the etiological agent of COVID-19, may cause new-onset diabetes persist amidst an evolving research landscape, and precise risk assessment is hampered by at times conflicting evidence. Here, leveraging comprehensive single-cell analyses of in vitro SARS-CoV-2-infected human pancreatic islets, we demonstrate that productive infection is strictly dependent on the SARS-CoV-2 entry receptor ACE2 and targets practically all pancreatic cell types. Importantly, the infection remains highly circumscribed, largely non-cytopathic, and despite high viral burden in infected subsets, promotes only modest cellular perturbations and inflammatory responses. Similar experimental outcomes are also observed after islet infection with endemic coronaviruses. Thus, the limits of pancreatic SARS-CoV-2 infection, even under in vitro conditions of enhanced virus exposure, challenge the proposition that in vivo targeting of beta cells by SARS-CoV-2 precipitates new-onset diabetes. If restricted pancreatic damage and immunological alterations accrued by COVID-19 increase cumulative diabetes risk, however, remains to be evaluated.

Ever since its prominent introduction in mid-2020, the concept of a "bidirectional relationship" between coronavirus disease 2019 and diabetes (Rubino et al., 2020) has been widely embraced, quoted and elaborated upon, conveying the impression of comparable evidentiary weight for both terms of the equation. Yet this would not appear to be the case. Broad and compelling evidence now supports the notion of diabetes and hyperglycemia as risk factors for aggravated COVID-19 course (Dennis et al., 2021; Lazarus et al., 2021; Sardu et al., 2020; Wu et al., 2020; Zhu et al., 2020) . In contrast, the proposition of SARS-CoV-2 infection as a trigger for new-onset diabetes has to contend with seemingly conflicting evidence about increased diabetes incidence rates during the COVID-19 pandemic as well as the considerable difficulties to distinguish an infectious diabetes origin from a multiplicity of pandemicrelated yet indirect potential causalities (Barrett et al., 2022; Drucker, 2021; Ibrahim et al., 2021; Kamrath et al., 2022; Khunti et al., 2021; Sathish et al., 2021) . While the aggregate epidemiological evidence ostensibly argues against a direct diabetogenic potential of SARS-CoV-2 infection, this assessment is certainly provisional in consideration of the manifold ramifications of pandemic containment measures; the evolving landscape of clinical studies; various diagnostic challenges (e.g., precise clinical definition of diabetes, previously undiagnosed type 1 or 2 diabetes [T1D or T2D] ); the different pathophysiological mechanisms promoting acute and/or prolonged glycometabolic perturbations (including hyperglycemia and insulin resistance typically associated with critical illness); and the possibility that a history of SARS-CoV-2 infection may alter diabetes incidence rates in the future (Al-Aly et al., 2021; Clarke et al., 2021; Drucker, 2021; Ibrahim et al., 2021; Jivanji et al., 2017; Kamrath et al., 2022; Li et al., 2020a; Misra et al., 2021; Montefusco et al., 2021; Reiterer et al., 2021) . Yet in the current context, a balanced evaluation of the available evidence also has to inform and delimit any speculation about the precise relevance of ex vivo and in vitro studies seeking to elucidate the potential for beta cell infection, incapacitation and/or destruction by SARS-CoV-2 (Accili, 2021; Atkinson and Powers, 2021) . Viral infections have long been hypothesized to play a role in T1D pathogenesis (Coppieters et al., 2012; Rodriguez-Calvo et al., 2016) , and to a lesser extent may also contribute to development of T2D (Turk Wensveen et al., 2021) . But more often than not, tantalizing speculations regarding the potential J o u r n a l P r e -p r o o f 4 diabetogenicity of specific viruses have not stood the test of time. A balanced assessment of the risk for SARS-CoV-2-induced diabetes has to integrate emerging epidemiological observations with complementary evidence from studies interrogating expression patterns of viral entry factors in the human pancreas, histopathology of COVID-19 pancreata, susceptibility of pancreatic tissue to in vitro SARS-CoV-2 infection, and novel animal models (Coate et al., 2020; Fignani et al., 2020; Hikmet et al., 2020; Kusmartseva et al., 2020; Muller et al., 2021; Qadir et al., 2021; Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021; Yang et al., 2020) . Yet work performed to this extent has at times generated conflicting results that in turn prompted notably divergent predictions about the potential risk for newonset diabetes (Drucker, 2021; Ibrahim et al., 2021; Qadir et al., 2021; Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021) . In the present study, we conducted comprehensive transcriptomic and proteomic single-cell analyses of in vitro SARS-CoV-2-infected primary human islets. Our results confirm the principal susceptibility of the exocrine and endocrine pancreas, including beta cells, to in vitro SARS-CoV-2 infection (Muller et al., 2021; Shaharuddin et al., 2021; Tang et al., 2021; Wu et al., 2021; . However, the mechanistic constraints, circumscribed extent, and limited consequences of viral infection in this model as well as its shared aspects with endemic coronavirus infections challenge the notion that direct SARS-CoV-2 targeting of beta cells can promote acute diabetes onset.

J o u r n a l P r e -p r o o f 5

To evaluate permissiveness of human pancreatic islet cells to in vitro SARS-CoV-2 infection, we employed a low multiplicity-of-infection (MOI) protocol that reliably infects ≥90% of susceptible Vero-E6 cells as revealed by flow-cytometric (FC) detection of the viral nucleoprotein (NP) (Fig.S1A/B ). We consider the use of a low MOI to be of particular importance since a surfeit of viral particles (including defective viral genomes and structural components with disrupted stoichiometry in viral stock preparations) potentiate interactions via pathogen-associated molecular patterns (PAMPs) that may promote enhanced IFN responses and cytopathic effects (CPEs) (Blanco-Melo et al., 2020; Daniloski et al., 2021; Miorin et al., 2020; Vignuzzi and Lopez, 2019) . A pertinent case in point is the observation that treatment of islets with recombinant SARS-CoV-2 spike (S) protein, i.e. in the absence of infection, causes beta cell death (Wu et al., 2021) . In our experiments, SARS-CoV-2 infected ~2.5% of islet cells, and despite considerable donor variability, beta cells (insulin/INS + ) were preferentially targeted over alpha cells (glucagon/GCG + ) while INS -GCG -"other" cells displayed intermediate infection levels (Fig.1A) . This pattern appears to segregate with the overall extent of infection since viral antigen was preferentially detected in beta or "other" cells in donors with above or below average infection, respectively (Fig.1B) .

Islet infection further proved productive as based on elevated infectious SARS-CoV-2 titers in the tissue culture supernatant (TCS) (Fig.1C ) yet without apparent infection enhancement after prolonged SARS-CoV-2 exposure (Fig.1D) . The latter aspect is consistent with other reports (Muller et al., 2021; Tang et al., 2021; Wu et al., 2021) and provides a rationale to focus our subsequent analyses on the earlier 48h time point. Here, a broad assessment of inflammation-associated TCS proteins (92 analytes) revealed a notably restrained inflammatory response involving the chemokines CXCL10 and CXCL11 (previously implicated in T1D pathogenesis (Christen and Kimmel, 2020; Homann, 2015) ) but only marginal levels of IFN (a potent inducer of CXCL10/11) and a minor downregulation of multiple proteins both positively and negatively associated with beta cell survival and diabetes development (Bhandage et al., 2018;  J o u r n a l P r e -p r o o f 6 Hanson et al., 2014; Kondegowda et al., 2015; Liadis et al., 2007; Mellado-Gil et al., 2011; Vendrell and Chacon, 2013) (Fig.1E/F ).

Human islet culture is inevitably associated with noticeable cellular death (Paraskevas et al., 2000) that needs to be distinguished from virus-induced CPEs. Accordingly, we determined the viral burden in both live and dead islet cells after mock vs. SARS-CoV-2 infection using amine-reactive dyes that label dead cells regardless of effector mechanisms operative in regulated cell death (Galluzzi et al., 2018; Perfetto et al., 2010) . While SARS-CoV-2 NP detection was comparatively reduced in dead beta cells, no significant differences were observed for live and dead alpha or "other" cells ( Fig.1G /H). Similarly, cell death among matched mock-infected and both NP -"bystander" and NP + infected cell subsets was equivalent in respective alpha and "other" cell compartments, and tentatively decreased for NP + beta cells (Fig.1I ) arguing against pronounced CPEs in SARS-CoV-2-infected islet cells. Nevertheless, noncytopathic viral infections may perturb cellular "luxury" functions (Oldstone et al., 1982) , and we note a small but significant reduction of insulin content specifically in infected beta cells that is in part driven by lower insulin expression in the dead cell compartment (Fig.1J ).

Productive SARS-CoV-2 infection is contingent on expression of multiple proviral host factors including the obligate SARS-CoV-2 entry receptor ACE2 (Baggen et al., 2021; Beumer et al., 2021) . To incorporate ACE2 detection into our assay platform, we employed a previously FC-validated antibody (polyclonal goat AF933) (Rathnasinghe et al., 2020b) noteworthy for its excellent performance and specificity in immunohistochemistry assays and immunoblotting of pancreatic protein extracts (Kusmartseva et al., 2020) . Here, ACE2 was detected on average on 4-5% of live alpha, beta and "other" cells but an important caveat pertains to the fact that AF933 binds to dead cells, an unexpected property also observed for another polyclonal goat ACE2 antibody (Poly5036) (Fig.S1C/D). We therefore demarcated stages of islet cell apoptosis and observed a relative increase of AF933 binding to early apoptotic beta but not alpha or "other" cells; in contrast nearly all late apoptotic and necrotic cells reacted with AF933 ( Fig.S1E/F ).

J o u r n a l P r e -p r o o f 7

The above caveats notwithstanding, AF933 was previously shown to block entry of SARS-CoV-2-Spseudotyped vesicular stomatitis virus (Hoffmann et al., 2020) , thereby providing an opportunity to functionally interrogate the role of ACE2 in SARS-CoV-2 infection of human islets. To this end, we defined the IC50 for AF933 on SARS-CoV-2-infected Vero-E6 cells (<10g/mL) (Fig.S2A/B) , and subsequently found that ACE2 blockade effectively prevents infection of alpha, beta and "other" cells (Figs.2A/B & S2C) . At the level of viral NP detection, we observed a 96% infection inhibition for beta and 94% inhibition for "other" cells ( Fig.2C ). ACE2 blockade also reduced infectious virus titers by 99.6% (Fig.2D ) but the accompanying inflammatory response profile was surprising (Fig.2E ). We first compared TCS protein expression levels from SARS-CoV-2 infections conducted in the absence (cf. Fig.1D /E) or presence of IgG control antibody and, predictably, recorded no differences. In contrast, ACE2-blockade potentiated secretion of chemokines (CXCL9/10 > CXCL11, CCL8 > CXCL5/6; CCL3/11/20), inflammatory cytokines (IL1A, IL17C, TNF, OSM) and 4E-BP1 without a concomitant reduction of other analytes (Fig.2E ). This pattern may be explained by the robust induction of IFN (Fig.2E ), likely in response to PAMP-mediated interactions that in the context of ACE2 blockade are no longer antagonized by the products of viral replication.

The possibility that hyperglycemia may facilitate SARS-CoV-2 infection was raised in a study using human monocytes cultured under conditions of escalating glucose concentration (Codo et al., 2020) . In our experiments, however, glucose concentration inversely correlated with ACE2 expression particularly in beta cells, and with SARS-CoV-2 infection of Vero-E6 cells (Fig.S2D-E) . For islets adapted to and maintained at varying glucose levels, however, no significant differences emerged at the level of cellular viral burden, infectious SARS-CoV-2 titers, or composition of inflammatory response parameters ( Fig.2F/G & S2G/H) . We further considered living pancreas slices as a more "physiological" experimental platform (Marciniak et al., 2014; Panzer et al., 2020) but specific culture conditions, in particular low J o u r n a l P r e -p r o o f 8 temperature (≤30 o C) and need for supplementation with protease inhibitors to maintain tissue integrity, pose a significant challenge to such studies (Fig.S2I ). Successful implementation may therefore require cold adaptation of the virus and judicious use of protease inhibitors to avoid interference with viral entry/replication.

To delineate transcriptional changes imparted by in vitro SARS-CoV-2 infection, we performed singlecell RNA-seq (scRNAseq) of matched mock-and virus-infected islets from three donors. Cell types were annotated by label transfer from public scRNAseq datasets (Baron et al., 2016; Grun et al., 2016; Lawlor et al., 2017; Muraro et al., 2016; Segerstolpe et al., 2016; Stuart et al., 2019) , which readily demarcated pancreatic cell subsets consistent across samples from all donors (Figs.3A & S3A). Within SARS-CoV-2-infected samples, cells were classified as "infected", "bystander", or "not assigned" based on unsupervised clustering of SARS-CoV-2 viral RNAs (Figs.3A & S3B). Of note, infected cells had significantly fewer host-derived transcript unique molecular identifiers (UMIs) per cell, fewer host genes detected per cell, and up to 75% of total sampled transcripts derived from viral genes (Fig.S3C) . Likely a consequence of virus-induced suppression of host transcription, we accordingly observed a reduction in cell type label transfer prediction scores for infected cells; nevertheless, annotated cell types expressed canonical marker genes across samples (Figs.S3D & S4A; Table S2 ).

Despite variable cell subset distribution across donors, we found no significant differences in cell type proportions (as annotated by cell type transfer) between infection conditions per donor (Fig.3B) , and in agreement with our earlier observations, infection assessed at the transcriptional level varied among donors and overall was rather limited (donor 1-3: infection of 0.2%, 2.0% and 3.4% of cells, respectively; Fig.3C ). Differential expression testing between infected, bystander, and mock cells revealed a broad downregulation of numerous transcripts in infected alpha cells (Table S3) . In beta cells, multiple interferon-stimulated genes (ISGs) were significantly induced in both infected and bystander cells; we also observed significant induction of NFκB-regulated genes associated with cellular stress in infected cells ( Fig.3D & Table S4 ) consistent with previous reports (Nilsson-Payant et al., 2021); and module J o u r n a l P r e -p r o o f 9 scores for "interferon alpha response," "interferon gamma response" and "TNF⍺ signaling via NFκB" Hallmark gene sets exhibited similar patterns (Fig.S4B) . Thus, in vitro SARS-CoV-2-infected beta cells express ISGs and stress response genes, and the strength of the bystander ISG response appears directly related to the extent of SARS-CoV-2 infection.

To provide greater proteomic detail about pancreatic cell types targeted by SARS-CoV-2 infection, we 

Leveraging the high dimensionality of MC, we proceeded to assess phenotypic alterations imparted by SARS-CoV-2 exposure. Infection of major endocrine cells modestly downregulated expression of J o u r n a l P r e -p r o o f 11 respective signature hormones without causing a "bystander effect" (i.e., no difference in S/NPvs. mockinfected cells; Fig.5A ). Further stratification into NP int and NP hi compartments allowed to associate reduced hormone expression particularly with high NP content (Figs.5B & S6A) , a likely corollary of host transcriptional suppression as discussed above. This phenomenon is most prominently evidenced by a significant reduction of HLA-ABC expression in virus-infected cells across all endocrine cell types, ACs, pericytes and ductal cells ( Fig.5B-D & S6B) . Interestingly, a trend towards increased HLA-ABC expression by S/NPcells is a consistent feature for all cell types ( Fig.5C /D) and constitutes the only example for a modest "bystander effect" at the protein level. In contrast, no differential regulation was observed for HLA-II expression by ductal cells, identified here as the major non-hematopoietic HLA-DR + cell type in the pancreas (Fig.5D) .

A broad survey of major phenotypic markers illustrates a more general pattern: absence of a "bystander effect" at the protein level, and maintenance or a trend towards downregulation in infected cell subsets, consistent with our speculation that viral transcription/translation interference is buffered by differential protein expression half-lives ( Fig.S6C /D). Such downregulation may also affect cellular "signature" markers (AC-expressed SUSD2, alpha cell-expressed CD26/TM4SF4) and TFs including those preferentially restricted to beta cells (PDX1/NKX6.1) (Fig.5F ). A notable exception is the increase of CD9 expression by infected endocrine cells (Fig.S6E ). Despite its prominent description as a beta cell subset marker (Dorrell et al., 2016) , its role in pancreatic endocrine cell biology remains unclear, and neither CD9 overexpression nor knockout altered differentiation, maturation or function of human pluripotent stem cell-derived beta cells (Li et al., 2020b) .

Tang et al. recently advanced the intriguing possibility that SARS-CoV-2 infection of beta cells may cause transdifferentiation as suggested by reduced insulin content and induction of alpha (e.g., GCG) and

acinar cell markers in >30% of beta cells (Tang et al., 2021) . Our own results, however, do not support this conclusion. Quantification of alpha and acinar cell markers in all ProINS + cells showed no significant differences in infected, bystander and mock-treated subsets (Fig.S7A ). Additional co-expression 12 analyses indicated that ~3% of ProINS + cells expressed GCG regardless of viral infection; the extent of viral infection in both GCGand GCG + ProINS + cell subsets was commensurate; and virus-infected GCG + ProINS + cells presented with a significant reduction of GCG content, slightly diminished TM4SF4 and unaltered CD26 levels ( Fig.S7B /C). In the absence of "bystander effects", these observations are consistent with an overall disruption of host gene transcription/translation in infected cell subsets.

Three recent publications further reported that several virus receptors (CD26, CD71, NRP1) are preferentially expressed by beta cells providing a potential explanation for their increased SARS-CoV-2 permissiveness (Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021) . However, in agreement with in situ immunostaining studies (Augstein et al., 2015) , CD26 was detected on alpha and ductal but not beta cells (Figs.4A & S7D/E), and despite initial speculation (Li et al., 2020c) is not a likely target for SARS-CoV-2 binding (Baggen et al., 2021; Beumer et al., 2021; Hoffmann et al., 2020; Schneider et al., 2021) . We similarly could not confirm differential CD71 expression by alpha and beta cells (Wu et al., 2021) since both cell types presented with the same low CD71 levels ( 

To better evaluate the degree to which our results may reveal aspects sufficiently unique to warrant speculation regarding SARS-CoV-2 diabetogenicity, we conducted experiments with two endemic (i.e., sparse targeting of beta-like, delta, ductal and unannotated cells but not alpha-like, gamma, acinar, ACs, pericytes or ECs); in dead cells, however, a higher viral burden was detectable especially in alpha, beta, delta, alpha-like and acinar cells while sparing ACs, pericytes and ECs (Fig.6C ).

Similar experiments were performed with the alphacoronavirus HCoV-NL63 that analogous to SARS-CoV-2 requires ACE2 for entry (Hofmann et al., 2005) . Fignani et al., 2020; Hikmet et al., 2020; Kusmartseva et al., 2020; Muller et al., 2021; Qadir et al., 2021; Shaharuddin et al., 2021; Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021; Yang et al., 2020) .

In the present study, we demonstrate that even under experimentally favorable in vitro conditions that enhance human islet exposure to the virus, SARS-CoV-2 promotes a productive yet largely circumscribed non-cytopathic infection; a muted inflammatory response; and only a modest array of cellular perturbations that are predominantly restricted to infected cell subsets. These constraints, which are also applicable to in vitro islet infections with endemic coronaviruses, should temper any considerations assigning a distinctive diabetogenic capacity to SARS-CoV-2.

Although SARS-CoV-2 infection is notably heterogeneous across different donors and islet preparations, its overall limited extent, which does not increase in the wake of prolonged in vitro virus exposure, is readily defined by both transcriptional and proteomic single-cell analyses where on average only 2-3% of islet cells carry viral message or antigen. At the same time, despite the substantial degree of viral replication in infected subsets (up to 75% of total cellular transcripts are of viral origin) and induction of prototypical ISG and stress response signatures, differential host transcript expression is restricted to fewer than three dozen genes, and a corresponding transcriptional "bystander effect" appears delimited by the overall extent of infection. Using a novel MC-based cell annotation strategy, we further demonstrate that the viral burden is differentially allocated to practically all pancreatic cell types including viruses not known to exhibit diabetogenic activity provides additional support for our caution to assign potential clinical significance to observations made with in vitro infection models for SARS-CoV-2.

Mechanistically, we show that in vitro infection of human islets is strictly dependent on ACE2. This is consistent with a recent formal demonstration that ACE2 operates as an obligate SARS-CoV-2 entry receptor (Beumer et al., 2021) and validates an earlier rationale to infer pancreatic susceptibility to SARS-CoV-2 infection from in situ ACE2 expression patterns (Coate et al., 2020; Fignani et al., 2020; Hikmet et al., 2020; Kusmartseva et al., 2020) . Here, however, an apparent consensus about ACE2 expression in microvasculature, ductal structures and pericytes contrasts with discordant results about its expression in endocrine cells (Drucker, 2021; Ibrahim et al., 2021) , a controversy also reflected in the most recent additions to this canon (Qadir et al., 2021; Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021) .

Considering the nature of pancreatic tissue specimens under investigation may offer a partial resolution to this conundrum: while we maintain that the scope of our earlier analyses and those by Coate et al. (Baggen et al., 2021) , likely shape differential susceptibility to SARS-CoV-2 infection, and the precise contribution of NRP1 and/or CD71 (Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021) in this context requires clarification considering their sparse endocrine cell expression as shown here.

Our main conclusions substantially differ from three recent reports where in vitro SARS-CoV-2 exposure promoted a ~10-fold higher rate of islet cell infection, excess cellular death and/or pronounced transcriptional, phenotypic, or functional alterations (Muller et al., 2021; Tang et al., 2021; Wu et al., 2021 ). An explanation for these differences, beyond specific donor and virus strain properties, may also come from an important caveat raised by our observation that prevention of infection by ACE2 blockade "paradoxically" potentiates the inflammatory response, namely that PAMPs present in the viral inoculum can elicit exaggerated cellular responses that do not reflect the specific consequences of viral infection.

Accordingly, our choice of a ~25-100-fold lower MOI than that reported by others (Muller et al., 2021; Tang et al., 2021; Wu et al., 2021) aims to better align in vitro experimentation with the comparatively low viral burden demonstrated in COVID-19 pancreata across several autopsy cohort studies (Bhatnagar et al., 2021; Chertow et al., 2021; Dorward et al., 2020; Schurink et al., 2020) . Specifically, subgenomic viral RNA indicative of active replication was detected only infrequently, at low levels and/or transiently (Chertow et al., 2021; Dorward et al., 2020; Tang et al., 2021) ; and SARS-CoV-2 protein co-localization with insulin-expressing beta cells appeared scarce though somewhat more pronounced for ductal cells and ECs (Bhatnagar et al., 2021; Kusmartseva et al., 2020; Muller et al., 2021; Qadir et al., 2021; Steenblock et al., 2021; Tang et al., 2021; Wu et al., 2021) . The challenges to derive consistent insights into the ramifications of in vivo pancreatic SARS-CoV-2 infection are also illustrated by three non-human primate studies that either failed to detect viral genomes in pancreata of 8/8 subjects (Munster et al., 2020) ; reported an absence of virus in pancreatic endocrine cells but correlated hyperglycemia in 2/8 subjects (~175 and 350mg/dl glucose, respectively) with thrombo-fibrotic lesions in the pancreas (Qadir et al., 2021) ; or documented beta cell-associated viral particles in 4/4 subjects as well as concomitant "beta cell atrophy" in the absence of enhanced cellular death (Millette et al., 2021) . Ultimately, however, J o u r n a l P r e -p r o o f 17 only examination of considerably more pancreatic autopsy tissues will permit a detailed assessment of the nature and scope of pancreatic COVID-19 pathology.

In our view, the hypothesis that direct SARS-CoV-2 infection of beta cells can precipitate new-onset diabetes is confounded by the fact that several key stages of presumed pathogenesis are relatively rare conditions or events (in situ ACE2 expression; susceptibility to in vitro infection; viral traces in the COVID-19 pancreas). Rather, more subtle damage to the pancreatic microenvironment in the wake of SARS-CoV-2 infection, including microvascular thrombosis, may compound to enhance future diabetes incidence in at-risk individuals (von Herrath et al., 2003) . Accordingly, a careful integration of emerging epidemiological studies, expanded histopathological investigations, development of novel animal models, and resolution of current controversies over the coming years will be required to formulate a balanced risk assessment of diabetes onset as a consequence of prior SARS-CoV-2 infection.

Our study has several apparent limitations. For one, the comparatively low number of islet donors, in particular for our scRNAseq work, does not permit a breakdown according to demographic or clinical parameters. We also refrained from conducting dynamic glucose-stimulated insulin secretion assays due to logistical challenges associated with work under BSL-3 conditions; we speculate, however, that a significant impairment for SARS-CoV-2-infected islet function is not likely to occur since a substantially higher extent of infection reportedly resulted in contradictory, unaltered or compromised insulin secretion, respectively (Muller et al., 2021; Tang et al., 2021; Wu et al., 2021) . Experimental outcomes are also delimited by the properties of specific SARS-CoV-2 variants and the details of in vitro infection protocols.

Although a comprehensive investigation into the impact exerted by these variables or combinations thereof is beyond the scope of the present study, we aim to strike a relevant balance by choice of a 

One or more of the authors of this paper received support from a program designed to increase minority representation in science. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dirk Homann (dirk.homann@mssm.edu).

This study did not generate new unique reagents.

scRNAseq data is available from the GEO repository database with accession number GSE194061. 10.17632/8gd78xxrcm.2). Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Human pancreatic islets for research purposes from non-diabetic cadaveric donors were obtained through Prodo Laboratories Inc. (Aliso Viejo, CA). Deidentified donor demographics as well as islet preparation characteristics are summarized in Table S1 . Upon receipt, islets were rested overnight in supplemented with 10% FBS, 1% penicillin-streptomycin, GlutaMAX supplement, 25 mM HEPES and 5% tryptose phosphate broth (Sigma). All cell lines were maintained at 37°C, 5% CO2 and >90% relative humidity.

The SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI Resources (NR-52281), propagated on and infectious viral titers were quantified by plaque assay on Vero-E6 monolayers as described (Ahmed et al., 1984) . All experiments and assays involving direct handling of SARS-CoV-2 as well as of potentially infectious samples prior to cellular fixation/viral inactivation were performed in a biosafety level (BSL)-3

setting; experiments/assays using other viruses were conducted under BSL-2+ conditions.

Vero-E6 cells were seeded at ~2x10 5 cells in 500 µl complete DMEM in tissue culture (TC)-treated 24well plates and cultured overnight. The medium was replaced with infection medium ( analogous fashion using 4.5x10 3 pfu/well HCoV-OC43 or 4.5x10 3 pfu/well HCoV-NL63. Infection with 2x10 4 pfu/well LCMV Armstrong clone 53b was performed as described (Korns Johnson and Homann, 2012) . Infections were allowed to proceed for 48-96h as indicated. To assess SARS-CoV-2 infection under conditions of escalating glucose concentrations, Vero-E6 cells were incubated in complete RPMI 1640 containing 5.5, 11.1, or 22.2 mM D-glucose, respectively. To determine SARS-CoV-2 infectivity in an experimental setting emulating pancreatic slice culture, Vero-E6 cells were additionally maintained in "slice medium" (Panzer et al., 2020) for 48h at 30°C in a humidified 5% CO2 incubator.

In vitro infections of primary human islets were performed in non-TC-treated 24-well plates at 3,000-4,000 islet equivalents (IEQs; due to compact islet size, one IEQ is estimated to consist of ~1,000 cells) per 500 µl complete RPMI 1640 ( 

To process virus-infected TCS under BSL-2+ conditions, a previously validated, germicidal ultraviolet C (UV-C; 254nm) device which irradiates at a median dose of 5.43 mWcm -2 was used to inactivate potentially infectious samples (Rathnasinghe et al., 2020a) . Briefly, to achieve stable UV-C output, the lamp was allowed to warm up for 4min prior to UV illumination of 50 μl aliquots of TCS in 96-well round-J o u r n a l P r e -p r o o f 29 bottom plates on ice for 4min as described (Rathnasinghe et al., 2020a) ; UV-C-treated supernatants were immediately stored at -80°C for follow-up assays.

Highly 

Flow cytometry was performed to analyze ACE2 surface expression in single cell suspensions of primary human islets cultured in PMI(T) for up to 48h after receipt. Briefly, dispersed islet cells were washed in FACS buffer (PBS with 1% FBS, 0.5% 3 mM sodium azide, and 0.5 mM EDTA; Sigma), stained for 40min at 4°C in the dark with goat anti-human ACE2 polyclonal goat antibody (AF933, R&D Systems) or normal goat IgG isotype control (AB-108-C, R&D Systems) conjugated to Alexa Fluor 647 (AF647; AF647 Antibody Labeling Kit, Life Technologies) followed by live/dead cell staining with Zombie NIR (Biolegend)

in PBS for 10min at RT. Note that cumulative impact of human islet isolation, transport, culture and dissociation required for FC analyses is associated with considerable cell death (Maachi et al., 2021; Paraskevas et al., 2000) . Cells were subsequently fixed and permeabilized using the FoxP3 transcription buffer kit (Life Technologies), and intracellularly stained for insulin (PE-anti-human insulin, Cell Signaling Technology) and glucagon (BV421-anti-human glucagon, BD Biosciences) for 40min at RT in the dark. 

Vero-E6 cell monolayers in TC-treated 24-well plates were preincubated for 2h at 37°C/5% CO2 with increasing concentrations of purified goat anti-human ACE2 (AF933, R&D systems) or irrelevant goat anti-human lipoprotein lipase polyclonal antibody (AF7917, R&D Systems) before 48h-infection with SARS-CoV-2 as detailed above. The half-maximal inhibitory concentration (IC50) was calculated based J o u r n a l P r e -p r o o f 31 on quantification of infectious TCS virus by plaque assay and detection of SARS-CoV-2 NP by FC.

Primary human islets (~4,000 IEQs/well in 500 µL complete RPMI 1640, 11.1 mM glucose) were pretreated with 10 µg/mL AF933 (targeting ACE2) or AF7917 (irrelevant goat IgG), infected with SARS-CoV-2 and both TCS and islets were harvested for subsequent analyses as specified.

Mass scRNAseq preprocessing: for combined human-virus transcriptome reference, annotations for previously reported SARS-CoV-2 (BetaCoV/Korea/KCDC03/2020) RNAs (Kim et al., 2020) were downloaded from the UCSC Genome Browser Table Browser (Fernandes et al., 2020) after filtering for TRS-dependent transcripts and score >900 and exported to gtf format. Transcripts for previously unknown ORFs were excluded, and an additional annotation for "viral genome RNA" covering the full length of the SARS-CoV-2 genome was manually added. Aligning the BetaCoV/Korea/KCDC03/2020 genome with USA/WA-CDC-WA1/2020 genome showed that the USA/WA-CDC-WA1/2020 reference contained an additional 21 3′ adenosine nucleotides. To account for this in our annotations, we extended any annotations from BetaCoV/Korea/KCDC03/2020 that ended at the 3′ end of the genome an additional 21 bases. To minimize redundancy in the SARS-CoV-2 annotation of subgenomic RNAs (sgmRNAs) and thereby mitigate the exclusion of "ambiguous" sequence reads from scRNAseq quantification (i.e. reads derived from viral sgmRNAs mapping to redundant 3′ transcription regions), the 3′ region of each sgmRNA was truncated at the most distal 5′ start of the subsequent ORF immediately downstream. This SARS-CoV-2 J o u r n a l P r e -p r o o f 33 reference transcriptome annotation was concatenated to human reference (GrCh38) and was then converted to a cellranger-compatible reference using cellranger/3.1.0 mkref (10X Genomics, Inc), and reads were aligned and quantified using cellranger/3.1.0 count. scRNAseq analysis: unfiltered cellranger-generated gene by cell matrices were analyzed in R/4.0.4 using Seurat/4.0.4 (Butler et al., 2018; Hafemeister and Satija, 2019; Macosko et al., 2015; Stuart et al., 2019) .

Because each donor sample was prepared independently, we assessed each dataset separately and set quality filters accordingly to exclude putative empty droplets, dead cells, and cell multiplets. Barcodes meeting the following filtering parameters were used for each sample: mock 1: 3,000 < total UMIs/cell < 15,000, 100 < total genes/cell < 4000, and percent mitochondrial gene expression < 15%; mock 2: 2,000 < total UMIs/cell < 15,000, 100 total genes/cell < 3,500, and percent mitochondrial gene expression < 10%; mock 3: 3,000 < total UMIs/cell < 15,000, 100 < total genes/cell < 4,000, and percent mitochondrial gene expression < 15%; infected 1: 3,000 < total UMIs/cell < 25,000, 10 < total genes/cell < 5,000, and percent mitochondrial gene expression < 10%; infected 2: 2,000 < total UMIs/cell < 15,000, 100 < total genes/cell < 3,500, and percent mitochondrial gene expression < 10%; infected 3: 3,000 < total UMIs/cell < 40,000, 10 < total genes/cell < 6,000, and percent mitochondrial gene expression < 15%. After filtering, data were scaled and normalized using SCTransform with regression for percent mitochondrial gene expression . Cells were annotated per sample by comparing to an integrated reference dataset of five pancreas scRNAseq datasets (Baron et al., 2016; Grun et al., 2016; Lawlor et al., 2017; Muraro et al., 2016; Segerstolpe et al., 2016; Stuart et al., 2019) were calculated using the Seurat function AddModuleScore for select Hallmark gene sets ("interferon alpha response," "interferon gamma response", "inflammatory response", and "TNF⍺ signaling via NFκB") using msigdbr/7.4.1 (Subramanian et al., 2005) .

Data handling, analysis, inter-/intra-experimental normalization and graphic representation were performed in Prism 6 and 8 (GraphPad). Data were tested for normal distribution using the Shapiro Wilk test and statistical significance was assessed by t-test, paired t-test and Mann Whitney U test for comparison between two groups as well as by repeated measures ANOVA with Tukey's multiple comparisons, or non-parametric Friedman test for analysis of more than two groups as specified. Data are displayed as mean ± SD unless indicated otherwise adopting the following convention: * (or #) p<0.05, ** (or ##) p<0.01, and *** (or ###) p<0.001. J o u r n a l P r e -p r o o f 35 .3) . Selected genes had a maximum p value within any infected or mock donor sample of 0.05. .3) . Selected genes had adjusted p values of less than 0.01 and absolute log2 fold changes values greater than log2(1.5). The table highlights the reagents, genetically modified organisms and strains, cell lines, software, instrumentation, and source data essential to reproduce results presented in the manuscript. Depending on the nature of the study, this may include standard laboratory materials (i.e., food chow for metabolism studies, support material for catalysis studies), but the table is not meant to be a comprehensive list of all materials and resources used (e.g., essential chemicals such as standard solvents, SDS, sucrose, or standard culture media do not need to be listed in the table). Items in the table must also be reported in the method details section within the context of their use. To maximize readability, the number of oligonucleotides and RNA sequences that may be listed in the table is restricted to no more than 10 each. If there are more than 10 oligonucleotides or RNA sequences to report, please provide this information as a supplementary document and reference the file (e.g., See Table S1 for XX) in the key resources table.

Please note that ALL references cited in the key resources table must be included in the references list. Please report the information as follows:

 REAGENT or RESOURCE: Provide full descriptive name of the item so that it can be identified and linked with its description in the manuscript (e.g., provide version number for software, host source for antibody, strain name). In the experimental models section (applicable only to experimental life science studies), please include all models used in the paper and describe each line/strain as: model organism: name used for strain/line in paper: genotype. (i.e., Mouse: OXTR fl/fl : B6.129(SJL)-Oxtr tm1.1Wsy/J ). In the biological samples section (applicable only to experimental life science studies), please list all samples obtained from commercial sources or biological repositories. Please note that software mentioned in the methods details or data and code availability section needs to also be included in the table. See the sample tables at the end of this document for examples of how to report reagents.

 SOURCE: Report the company, manufacturer, or individual that provided the item or where the item can be obtained (e.g., stock center or repository). For materials distributed by Addgene, please cite the article describing the plasmid and include "Addgene" as part of the identifier. If an item is from another lab, please include the name of the principal investigator and a citation if it has been previously published. If the material is being reported for the first time in the current paper, please indicate as "this paper." For software, please provide the company name if it is commercially available or cite the paper in which it has been initially described.

 IDENTIFIER: Include catalog numbers (entered in the column as "Cat#" followed by the number, e.g., Cat#3879S). Where available, please include unique entities such as RRIDs, Model Organism Database numbers, accession numbers, and PDB, CAS, or CCDC IDs. For antibodies, if applicable and available, please also include the lot number or clone identity. For software or data resources, please include the URL where the resource can be downloaded. Please ensure accuracy of the identifiers, as they are essential for generation of hyperlinks to external sources when available. Please see the Elsevier list of data repositories with automated bidirectional linking for details. When listing more than one identifier for the same item, use semicolons to separate them (e.g., Cat#3879S; RRID: AB_2255011). If an identifier is not available, please enter "N/A" in the column. o A NOTE ABOUT RRIDs: We highly recommend using RRIDs as the identifier (in particular for antibodies and organisms but also for software tools and databases). For more details on how to obtain or generate an RRID for existing or newly generated resources, please visit the RII or search for RRIDs.

Please use the empty table that follows to organize the information in the sections defined by the subheading, skipping sections not relevant to your study. Please do not add subheadings. To add a row, place the cursor at the end of the row above where you would like to add the row, just outside the right border of the table. Then press the ENTER key to add the row. Please delete empty rows. Each entry must be on a separate row; do not list multiple items in a single table cell. Please see the sample tables at the end of this document for relevant examples in the life and physical sciences of how reagents and instrumentation should be cited.

Can COVID-19 cause diabetes?

Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence

High-dimensional characterization of post-acute sequelae of COVID-19

Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes?

Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells

Cellular host factors for SARS-CoV-2 infection

A Single-Cell Transcriptomic Map of the Human and Mouse Pancreas Reveals Inter-and Intra-cell Population Structure

Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years -United States

A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses

GABA Regulates Release of Inflammatory Cytokines From Peripheral Blood Mononuclear Cells and CD4(+) T Cells and Is Immunosuppressive in Type 1 Diabetes

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Series

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The UCSC SARS-CoV-2 Genome Browser

SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type

Is Expressed in Human Pancreatic beta-Cells and in the Human Pancreas Microvasculature

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death

De Novo Prediction of Stem Cell Identity using Single-Cell Transcriptome Data

Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression

A genome-wide association study in American Indians implicates DNER as a susceptibility locus for type 2 diabetes

The protein expression profile of ACE2 in human tissues

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Back From the Brink: The Uses of Targeting the CXCL10:CXCR3 Axis in Type 1 Diabetes

Human coronaviruses OC43 and HKU1 bind to 9-Oacetylated sialic acids via a conserved receptor-binding site in spike protein domain A

Not so sweet and simple: impacts of SARS-CoV-2 on the beta cell

New-Onset Diabetes After Acute and Critical Illness: A Systematic Review

Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19

COVID-19, Hyperglycemia, and New-Onset Diabetes

The Architecture of SARS-CoV-2 Transcriptome

Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-kappaB Ligand Pathway

Accelerated and improved quantification of lymphocytic choriomeningitis virus (LCMV) titers by flow cytometry

Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19

Single-cell transcriptomes identify human islet cell signatures and reveal celltype-specific expression changes in type 2 diabetes

High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis

COVID-19 infection may cause ketosis and ketoacidosis

Single-Cell RNA-Seq Reveals that CD9 Is a Negative Marker of Glucose-Responsive Pancreatic beta-like Cells Derived from Human Pluripotent Stem Cells

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

Distinct in vivo roles of caspase-8 in beta-cells in physiological and diabetes models

Pronounced proliferation of non-beta cells in response to beta-cell mitogens in isolated human islets of Langerhans

Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets

Using pancreas tissue slices for in situ studies of islet of Langerhans and acinar cell biology

Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes

SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study

Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

A Single-Cell Transcriptome Atlas of the Human Pancreas

The NF-kappaB transcriptional footprint is essential for SARS-CoV-2 replication

Virus-induced alterations in homeostasis: alteration in differentiated functions of infected cells in vivo

Early events during human coronavirus OC43 entry to the cell

Pancreas tissue slices from organ donors enable in situ analysis of type 1 diabetes pathogenesis

Cell loss in isolated human islets occurs by apoptosis

Amine-reactive dyes for dead cell discrimination in fixed samples. Current protocols in cytometry / editorial board

SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes

Mass cytometry and type 1 diabetes research in the age of single-cell data science

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera

Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultra-violet C (UVC) irradiation device

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance. medRxiv

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes

The viral paradigm in type 1 diabetes: Who are the main suspects?

New-Onset Diabetes in Covid-19

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?

Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis

Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes

Deleterious Effects of SARS-CoV-2 Infection on

Viral infiltration of pancreatic islets in patients with COVID-19

Comprehensive Integration of Single-Cell Data

Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles

SARS-CoV-2 infection induces beta cell transdifferentiation

Type 2 diabetes and viral infection; cause and effect of disease

TWEAK: A New Player in Obesity and Diabetes

Defective viral genomes are key drivers of the virus-host interaction

Microorganisms and autoimmunity: making the barren field fertile?

SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment

Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

We thank the families of the organ donors for the gift of tissues. We would like to acknowledge the expertise and assistance of the Dean's Flow Cytometry CORE at Mount Sinai as well as Jill Gregory who designed the Graphical Abstract, printed here with permission from ©Mount Sinai Health System. These 

Cat# 565891; RRID: AB_2739381 Anti-human GFAP (mouse IgG2b, clone 1B4) -156Gd (in-house conjugation)

Cat# 556328; RRID: AB_396366 Anti-human GHRL (rat IgG2a, clone 883622) -168Er (in-house conjugation)

Cat# MAB8200; RRID: AB_2637039 Anti-human NKX2.2 (mouse IgG2a, clone 74.5A5) -162Dy (inhouse conjugation)

Cat# 564731; RRID: AB_2738924 Anti-human NKX6.1 (mouse IgG1, clone R11-560) -164Dy (inhouse conjugation)